This activity is supported by an unrestricted educational grant from Bristol-Myers Squibb and Merck & Co.

Evolving Paradigms in Melanoma Therapy

Anthony J. Olszanski, MD, RPH,
Fox Chase Cancer Center

Brianna Hoffner, MS, ANP-BC, AOCNP
The Angeles Clinic and Research Institute

Learn the science behind immune response and treatment options for Melanoma. This activity provides an overview of differentiating checkpoint inhibitors from options such as kinase inhibitors, and cytotoxic chemotherapy. Discuss potential toxicities, care management, and the AP role in the collaborative practice approach to patient care.

Download Podcast

Download Transcript

Download Slides

Download Slides & Transcripts

Related Material

How does the combination of CTLA-4 and PD-1 agents enhance treatment outcomes for melanoma patients?

How should biomarkers for CTLA-4 and PD-L1 be integrated in patients with melanoma?

In the era of high response rates seen in immunotherapy combinations and targeted therapy combinations, how do you sequence therapies?

Do you have any practical "take-away" clinical tips for APs in the community setting caring for melanoma patients on immunotherapy?

How do immune-related adverse events differ from toxicities seen in targeted or chemotherapies?

These CME/CE/CPE accredited activities are jointly provided by